Burke T. Barrett is a seasoned executive in the medical device and biotechnology industries, with over three decades of experience driving innovation and growth in healthcare technologies. He began his career in engineering and product development at prominent firms like Baxter International and CardioThoracic Systems, where he honed his expertise in cardiovascular devices and minimally invasive surgical tools. Barrett's leadership roles expanded to include strategic positions at companies such as SynCardia Systems, where he served as President and CEO, overseeing the development of artificial heart technologies that earned FDA approvals and improved patient outcomes worldwide. His educational foundation includes a Bachelor of Science in Mechanical Engineering from the University of Notre Dame and an MBA from Northwestern University's Kellogg School of Management, which equipped him with a blend of technical acumen and business strategy. At Pulse Biosciences Inc., Barrett served as Chief Executive Officer and Director from 2019 until his recent departure, playing a pivotal role in advancing the company's proprietary Nano-Pulse Stimulation (NPS) technology platform. Under his guidance, Pulse Biosciences made significant strides in clinical trials and regulatory milestones, focusing on applications in oncology, dermatology, and immunology. Barrett spearheaded key partnerships and funding initiatives that bolstered the company's pipeline, including the successful navigation of FDA clearances for investigational devices aimed at treating skin lesions and other conditions. His tenure was marked by a commitment to ethical innovation, fostering a culture of scientific rigor and patient-centered development that positioned Pulse Biosciences as a leader in bioelectric medicine. Beyond his corporate achievements, Barrett has been recognized for his contributions to the medtech sector, including serving on advisory boards for industry associations and mentoring emerging startups. His legacy at Pulse Biosciences includes laying the groundwork for sustainable growth and therapeutic breakthroughs, leaving the company well-poised for future advancements in non-thermal cellular signaling technologies.